Neurology® Podcast

1) Progesterone versus placebo therapy for women with epilepsy and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Chenjie Xia interviews Dr. Andy Herzog about his paper on progesterone versus placebo therapy for women with epilepsy. Dr. Stacey Clardy is reading our e-Pearl of the week about myotonia congenita. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about bedside testing of memory. The participants had nothing to disclose except Drs. Herzog, Clardy, Burns and Buonomano.Dr. Herzog serves as an editorial board member of Epilepsy & Behavior.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.

1) Measures of health-related quality of life and 2) Topic of the month: Memory. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. David Cella about his paper on measures of health-related quality of life. Dr. Stacey Clardy is reading our e-Pearl of the week about frontotemporal dementia. In the next part of the podcast Dr. Ted Burns interviews Dr. Dean Buonomano about major categories of memory. Next week they will discuss bedside testing of memory. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Cella serves on the scientific advisory boards of the Moffitt Cancer Center, NCI Symptom Management and Health-Related Quality of Life (SxQOL) Steering Committee, serves as Associate Editor of The Journal of Supportive Oncology; is a consultant for Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, and GlaxoSmithKline; receives royalties from Up-to-Date annual review of Quality of life measures; receives research support from Pfizer Inc, Genetech, Inc., Novartis, Bayer Schering Pharma, GlaxoSmithKline and AVEO Pharmaceuticals, Inc.; and is funded by the NIH.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Buonomano receives royalties from the publication of the book Brain Bugs: How the brain's flaws shape our lives.

Clinical Diagnostic Reasoning and Physician Cognitive Errors

1) Cognitive effects of one season of head impacts 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Thomas McAllister about his paper on cognitive effects of one season of head impacts. Dr. Jennifer Fugate is reading our e-Pearl of the week about Hashimoto encephalopathy. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about preclinical Alzheimer disease. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. All participants have disclosures.Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; received royalties for an entry in Up-to-date entitled: The choking game and other strangulation activities in children and adolescents and is funded by NIH grants.Dr. McAllister is funded by NIH grants.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Small fiber neuropathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Steve Waxman about his paper on small fiber neuropathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about diffusion-weighted imaging. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about other biomarkers for mild cognitive impairment and Alzheimer disease. Next week they will discuss preclinical Alzheimer disease. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Waxman serves on the editorial boards of Clinical Neuroscience, The Neurologist, Neurobiology of Disease, Clinical Neurology and Neurosurgery, SYNAPSE, Molecular Neurobiology, Clinical Neuroscience Research, Neuron-Glia Biology, Neurotherapeutics, Trends in Molecular Medicine, Molecular Pain and Channels; served on the editorial board Journal of Neurotrauma; serves on the scientific advisory board for Brain and Nature Reviews Neurology; Editor-in-Chief of The Neuroscientist and Neuroscience Letters; Editor of The Journal of Physiology; Section Head Multiple Sclerosis, Faculty of 1000 Medicine; is or has been a consultant for Cardiome Pharmaceutical, Bristol-Myers Squibb, Vertex Pharmaceutical, ChromaCell and DaiNippon Sumitomo Pharmaceuticals; receives research support from Pfizer Inc., The Erythromelalgia Association and Department of Veterans Affairs; holds stock options in SITE ONE Research for serving on its Advisory Board and is listed as an inventor for a patent held by Yale University on the Invention of sodium channel NaV1.9.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Newly diagnosed epilepsy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jen Langer interviews Prof. Martin Brodie about his paper on newly diagnosed epilepsy. Dr. Jennifer Fugate is reading our e-Pearl of the week about nocturnal wandering in adults. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about imaging modalities for diagnosis of mild cognitive impairment and Alzheimer disease. Over the next two weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. The participants had nothing to disclose except Prof. Brodie, Drs. Fugate, Burns and Morris.Prof. Brodie serves on the editorial boards of Seizure, Epilepsy & Behavior, CNS Drugs and Acta Neurologica Scandinavia; serves on scientific advisory boards for Pfizer Inc, UCB, Eisai Inc., GlaxoSmithKline, Novartis, Sanofi-aventis, Upsher-Smith Laboratories, Inc. and Lundbeck Inc; has received funding for travel from UCB; serves as a consultant for Eisai Inc.; serves on speakers' bureaus for UCB, GlaxoSmithKline, and Eisai Inc.; and has received research support from GlaxoSmithKline, and Eisai Inc.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) A case of Necrotizing myopathy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Mammen interviews Prof. Michael Hanna about his paper on necrotizing myopathy. Dr. Jennifer Fugate is reading our e-Pearl of the week about unilateral clubbing in hemiplegia. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of Alzheimer disease. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.Dr. Mammen has served as an expert witness for trials in 2010 and 2011; receives revenue for a patent on anti-HMGCR antibody detection technology; and received honoraria for Grand Round presentations at several universities.Prof. Hanna receives research funding from the Medical Research Council, MRC Center grant (G0601943), from the Muscular Dystrophy Campaign and the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) NIH grant U54 NS059065. M.G. Hanna provides the UK national patient referral center for skeletal muscle channelopathies funded by the UK Department of Health National Commissioning Group. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

Neuromuscular Junction Disorders

1) Simultaneous PML-IRIS in MS and 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Igor Koralnik about his paper on simultaneous PML-IRIS in an MS patient. Dr. Jennifer Fugate is reading our e-Pearl of the week about traumatic brain injury. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of mild cognitive impairment. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.Dr. Keegan serves as eMedicine Chief Editor and is a consultant for Bionest and Novartis. Dr. Koralnik serves on the editorial board of the Journal of NeuroVirology; served on the scientific advisory boards for Hoffman-La Roche Inc., GlaxoSmithKline and Merck Serono; receives royalties from UpToDate, Inc.; has served as a consultant for Bristol-Myers Squibb, Ono Pharmaceuticals Co. LTD., Merck Serone, Hoffman-La Roche Inc., GlaxoSmithKline, Perseid Therapeutic LLC; Vertex Pharmaceuticals; and Johnson & Johnson; receives research support from NIH; and has received research support from Biogen Idec and the National Multiple Sclerosis Society.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.

1) Evidence-based guideline updates on episodic migraine prevention and 2) Topic of the month: Obesity and the neurology patient. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Drs. Stephen D. Silberstein and Starr Holland on the guideline updates about treatments for episodic migraine prevention in adults. Dr. Chafic Karam is reading our e-Pearl of the week about scapular winging. In the next part of the podcast Dr. Ted Burns interviews Dr. Lisa Davis about her recent paper titled: Clinical strategies for managing the overweight neurology patient published in the March Neurology Clinical Practice Journal. All participants have disclosures.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, CAPNIA, Coherex Medical, GlaxoSmithKline, Iroko Pharmaceuticals, LLC, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, and St. Jude Medical; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Allergan, Inc., Endo Pharmaceuticals, GlaxoSmithKline, Zogenix, and Merck Serono; serves as a consultant for Amgen, Nautilus, Inc., Novartis, Opti-Nose, and Zogenix; receives publishing royalties for Wolff's Headache, 8th edition (Oxford University Press, 2009) and Handbook of Headache (Cambridge University Press, 2010); his employer receives research support from Allergan, Endo, GlaxoSmithKline, MAP, Merck Serono, the NIH/NINDS, Novartis, and Neurolieve; receives research support from the American Headache Society and the International Headache Society.Dr. Holland serves as a consultant for MAP Pharmaceuticals, Inc.; receives research support from Albert Einstein College of Medicine and the American Headache Society.Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Davis serves as a consultant for Medifast, Inc. and the Coleman Research Group and is a shareholder in Medifast, Inc.